Needham & Company Maintains a 'Strong Buy' on Par Pharmaceutical (PRX); 3Q11 Meets Expectations as Key Products Continue Strong Pace
Get Alerts PRX Hot Sheet
Price: $49.98 --0%
Rating Summary:
1 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 0
Rating Summary:
1 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 0
Join SI Premium – FREE
Needham & Company maintains a 'Strong Buy' on Par Pharmaceutical (NYSE: PRX) price target raised $3 to $41.00.
Needham analyst says, "A strong performance from key generics allowed PRX to post 3Q11 numbers that outpaced and met expectations for the top- and bottomline, respectively. Given that the strength of key generic products is not expected to subside in short-term and the recent launch of generic olanzapine ODT (Zyprexa Zydis), near-term visibility on numbers remains high. Taking a longer-term view, the recent acquisition of Anchen Pharmaceuticals and the divested Teva-Cephalon products has not only upgraded the manufacturing and development capabilities of PRX but strengthened the product pipeline and added significant visibility to 2012 EPS and beyond. We continue to believe that the current valuation combined with the continuing strength in key generics, the resurgent branded business and the recent transactions provides a case where the upside potential outweighs the downside risk."
For more ratings news on Par Pharmaceutical click here and for the rating history of Par Pharmaceutical click here.
Shares of Par Pharmaceutical closed at $29.72 yesterday.
Needham analyst says, "A strong performance from key generics allowed PRX to post 3Q11 numbers that outpaced and met expectations for the top- and bottomline, respectively. Given that the strength of key generic products is not expected to subside in short-term and the recent launch of generic olanzapine ODT (Zyprexa Zydis), near-term visibility on numbers remains high. Taking a longer-term view, the recent acquisition of Anchen Pharmaceuticals and the divested Teva-Cephalon products has not only upgraded the manufacturing and development capabilities of PRX but strengthened the product pipeline and added significant visibility to 2012 EPS and beyond. We continue to believe that the current valuation combined with the continuing strength in key generics, the resurgent branded business and the recent transactions provides a case where the upside potential outweighs the downside risk."
For more ratings news on Par Pharmaceutical click here and for the rating history of Par Pharmaceutical click here.
Shares of Par Pharmaceutical closed at $29.72 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Walt Disney (DIS) PT Raised to $145 at Needham
- Celcuity Inc (CELC) PT Raised to $24 at Needham
- DraftKings (DKNG) target raised as Needham & Company adds stock to Conviction List
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Needham & CompanySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!